FOS and neoplasm: This combination strategy offers a clinically relevant approach to improve treatment efficacy and overcome resistance in EC patients.[45] These results collectively demonstrate that PEITC's anti‐tumor efficacy is not solely due to general cytotoxicity, but is driven by its specific inhibition of the SF3A3–c‐FOS oncogenic axis.